Skip to main content
. 2014 Apr 17;4:4721. doi: 10.1038/srep04721

Table 1. Structures and activities of reutericyclin analogs.

Number   MIC (μg/ml) against Gram-positive bacteria
R1 R2CO R3 EF SP SPn BA BS CD MSSA MRSA  
1     CH3 0.20 6.25 3.13 0.20 0.39 0.09 0.78 0.4
2 H >200 >200 >200 >200 >200 >128 >200 >200
3   50 12.5 6.25 >200 100 16 50 12.5
4   12.5 25 3.13 >200 25 8 12.5 1.6
5   0.78 3.13 0.78 >200 1.56 0.25 0.78 <0.1
6   (CH2)CH3 0.20 3.13 3.13 0.39 0.39 <0.03 <0.1 <0.1
7   0.39 12.5 12.5 >200 0.78 0.75 <0.1 <0.1
8   50 100 25 50 100 0.5 25 12.5
9   50 100 50 12.5 12.5 8 50 50
10   0.39 3.13 3.13 0.78 1.56 0.25 0.40 0.2
11   0.78 25 12.5 0.20 1.56 0.25 0.78 0.2
12   12.5 50 50 0.78 3.13 2 6.25 6.25
13   0.20 6.25 12.5 0.39 0.39 <0.03 0.20 <0.1
14 H CH3 6.25 50 12.5 1.56 12.5 2 12.5 3.2
15   100 50 100 >200 200 64 >200 >200
16   25 50 25 >200 50 >64 >200 >200
17   50 >200 >200 >200 >200 >64 100 200
18   6.25 25 12.5 >200 12.5 4 6.25 0.8
19   50 50 25 200 50 32 50 25
20   0.78 12.5 6.25 200 1.56 0.25 <0.1 <0.1

Abbreviations: EF - Enterococcus faecalis ATCC 33186, SP - Streptococcus pyogenes ATCC 700294, SPn - Streptococcus pneumoniae R6, BA - Bacillus anthracis sterne, BS - Bacillus subtilis ATCC 23857, CD - Clostridium difficile BAA 1803, MSSA - methicillin-susceptible Staphylococcus aureus Newman, MRSA – methicillin-resistant Staphylococcus aureus N315.